Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie

 
• By Jessica Merrill

Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.

hand shake
Neuocrine signed a licensing deal with Sosei Heptares • Source: Alamy

More from Deals

More from Business